PM8002

Phase 3Biologic

BBiotheus Inc.

PM8002 is one of 133 biologic programs targeting Neuroendocrine Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine NeoplasmActive, not recruiting

ChemotherapyActive, not recruiting

CRC (colorectal Cancer)Recruiting

Triple NegativeActive, not recruiting

Patients With Advanced Solid TumorsRecruiting

Neoadjuvant ChemotherapyNot yet recruiting

First-LineNot yet recruiting

Neuroendocrine NeoplasmPhase 2

Active, not recruiting

ChemotherapyPhase 2

Active, not recruiting

CRC (colorectal Cancer)Phase 2

Recruiting

Triple NegativePhase 3

Active, not recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Neoadjuvant ChemotherapyPhase 2

Not yet recruiting

First-LinePhase 2

Not yet recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

19 2

Eloxatin

Teva

Phase 2

9 3

Tecentriq

Roche

Phase 2

4 4

Camptosar

Pfizer

Phase 2

4 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

15 6

Erbitux

IImclone

Phase 2

9 7

Tuoyi

CCoherus Oncology, Inc.

Phase 2

9 8

Lazcluze

Johnson & Johnson

Phase 2

1 9

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

6 10

PM8002

BBiotheus Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Not yet recruiting

First-Line

NCT06584071

Q1 2028

Phase 2Active, not recruiting

Neuroendocrine Neoplasm

NCT05879055

Q3 2028

Phase 3Active, not recruiting

Triple Negative

NCT06419621

Q4 2028

Phase 3Active, not recruiting

SCLC

NCT06616532

Clinical

Trials by Indication[1]

Chemotherapy3 trials

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Active, not recruiting·BBiotheus Inc.·Phase 2·NCT05756972·64 enrolled

A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Active, not recruiting·BBiotheus Inc.·Phase 2·NCT05879068·99 enrolled

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Active, not recruiting·BBiotheus Inc.·Phase 2·NCT05844150·50 enrolled

First Line Therapy2 trials

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active, not recruiting·BBiotheus Inc.·Phase 1/2·NCT05918133·42 enrolled

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Recruiting·BBiotheus Inc.·Phase 2·NCT05918107·55 enrolled

Patients With Advanced Solid Tumors1 trial

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting·BBiotheus Inc.·Phase 1/2·NCT05918445·380 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06837948·160 enrolled

First-line1 trial

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Not yet recruiting·BBiotheus Inc.·Phase 1/2·NCT06584071·140 enrolled

5 more indications

SCLC1 trial

A Multicenter, Open-lable, Randomized Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Active, not recruiting·BBiotheus Inc.·Phase 3·NCT06616532·404 enrolled

Triple Negative1 trial

A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)

Active, not recruiting·BBiotheus Inc.·Phase 3·NCT06419621·392 enrolled

CRC (Colorectal Cancer)1 trial

A Phase II, Multicenter, Open Label, Parallel Cohort Clinical Trial to Evaluate the Efficacy and Safety of PM8002 (BNT327) in Combination With Chemotherapy in First Line MSS or MSI-L/pMMR Metastatic Colorectal Cancer

Recruiting·BBiotheus Inc.·Phase 2·NCT07133750·100 enrolled

Neuroendocrine Neoplasm1 trial

A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm

Active, not recruiting·BBiotheus Inc.·Phase 2·NCT05879055·31 enrolled

Hepatocellular Carcinoma1 trial

A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in Unresectable Hepatocellular Carcinoma

Completed·BBiotheus Inc.·Phase 2·NCT05864105·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for PM8002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PM8002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PM8002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biotheus Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: BBiotheus Inc.

PM8002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q3 2028

Q4 2028

Trials by Indication[1]

Chemotherapy3 trials

First Line Therapy2 trials

Patients With Advanced Solid Tumors1 trial

Neoadjuvant Chemotherapy1 trial

First-line1 trial

SCLC1 trial

Triple Negative1 trial

CRC (Colorectal Cancer)1 trial

Neuroendocrine Neoplasm1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News